期刊文献+

表皮生长因子受体信号通路及其靶向肿瘤治疗 被引量:8

Signal pathway mediated by epidermal growth factor receptor and applications for targeted cancer therapy
下载PDF
导出
摘要 表皮生长因子受体(EGFR)属于蛋白酪氨酸激酶受体家族。在特异配体的刺激下,EGFR可激活PI3K-Akt和Ras-Raf-MEK-ERK等多条信号通路。EGFR的异常高表达或突变可见于多种恶性肿瘤,并与肿瘤的恶性生物学行为和患者的不良预后密切相关。目前针对EGFR及其下游信号转导子已开发出多种抗肿瘤药物。这些药物疗效高,副作用小,具有良好的应用前景。
出处 《国外医学(肿瘤学分册)》 2005年第5期361-364,共4页 Foreign Medical Sciences (Cancer Section)
  • 相关文献

参考文献1

二级参考文献13

  • 1Cohen MH,Williams GA,Sridhara R,et al.FDA drug approval summary:Gefitinib(ZD1839)(Iressa) tablets [J].Oncologist,2003,8(4):303-306.
  • 2Zhu XF,Liu ZC,Xie BF,et al.EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells [J].Cancer Letters,2001,169:27-32.
  • 3Sun Y,Fry DW,Vincent P,et al.Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors [J].Anticancer Res,1999,19:919-924.
  • 4Savini EC.The antagonism between 5-hydroxytryptamine and certain derivatives of lysergic acid [J].Br J Pharmacol,1956,11(3):313-317.
  • 5Salomon DS,Brandt R,Ciardiello F,et al.Epidermal growth factor-related peptides and their receptors in human malignancies[J].Crit Rev Oncol Hematol,1995,19:183-232.
  • 6Ranson M.ZD1839(IRESSA):For more than just non-small cell lung cancer [J].The Oncologist,2002,7(suppl 4):16-24.
  • 7Ciardiello F,Caputo R,Bianco R,et al.Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839(Iressa),a selective epidermal growth factor receptor tyrosine kinase inhibitor [J].Clin Cancer Res,2001,7(5):1459-1465.
  • 8Ciardiello F,Caputo R,Bianco R,et al.Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839(Iressa),an epidermal growth factor receptor-selective tyrosine kinase inhibitor [J].Clin Cancer Res,2000,6(5):2053-2063.
  • 9Baselga J,Rischin D,Ranson M,et al.Phase Ⅰ safety,pharmacokinetic,and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types [J].J Clin Oncol,2002,20(21):4292-4302.
  • 10Herbst RS,Maddox AM,Rothenberg ML,et al.Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is well-tolerrated and has activity in non-small-cell lung cancer and other solid tumors:results on a phase Ⅰ trial [J].J Clin Oncol,2002,20(18):3815-3825.

共引文献11

同被引文献71

引证文献8

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部